Page 1234 - Basic _ Clinical Pharmacology ( PDFDrive )

1220 Index

Inhibin rapid-acting, 754 Intestinal metabolism, in first-pass effect, 58
in ovary, 732 regimens for, 766 Intestinal osteodystrophy, 786
in testis, 740 regulation of release of, 758t Intestinal sterol absorption inhibitors, 637,
Inhibitors. See also Antagonist; specific types secretion of, 748, 749f 640t
acetylcholinesterase, 5 short-acting, 753–754 Intracellular receptors, for lipid-soluble
allosteric, 5, 6f types of, 754 agents, 27, 27f
competitive, 5, 6f tyrosine kinase receptors for, 28 Intraocular pressure, 165b, 267
suicide, 61 Insulin-like growth factor-I (IGF-I), Intraoperative floppy iris syndrome (IFIS),
Inhibitory postsynaptic potential (IPSP), 669 160
103, 103f, 371, 371f Insulin pumps, 756–757 Intravenous immunoglobulins (IGIV),
Innate immune system, 977–979 Insulin receptor, 748–749, 749f, 750t 990–991
Inositol-1,4,5-trisphosphate (IP3, InsP3), Insulin receptor substrates, 749 Intravenous lipid emulsion, 469b
33, 34f, 138f, 139, 139t Insulin resistance, 757, 771 Intrinsic efficacy, 5
Inotropes, positive Insulin secretagogues Intrinsic factor, 596
in elderly, 1064 meglitinide analogs, 759, 769t Intubation, endotracheal, 484–485
heart failure treated with, 219–221 sulfonylureas, 757–759, 769t. See also Inverse agonists
acute, 224 Sulfonylureas b-receptor antagonist drugs as, 162
beta-adrenoceptor agonists, 219 Integrase strand transfer inhibitors (INSIs), description of, 5–6, 7f, 23, 387
bipyridines, 219 883–884 Investigational New Drug (IND), 12f,
digitalis, 217–219, 218t, 219f, 226t dolutegravir, 871t, 883 15–17
investigational, 219–220 elvitegravir, 871t, 883 Iodide
istaroxime, 219 fundamentals of, 883 metabolism of, 687
levosimendan, 219 raltegravir, 872t, 884 organification of, 688, 688f
omecamtiv mecarbil, 219–220 Integrins, 1112 Iodides, 695, 701t
Insecticides Intensity of exposure, 1005 Iodine
organophosphates, 115–117, 116f Intention tremor, 504 bactericidal, 899
131
thiophosphates, 116f, 117 Intercalated cells, 258, 258f radioactive ( I, RAI), 695–696, 701t
Insertions/deletion (indel), 75t Interferon-α Iodism, 695
Insomnia description of, 996, 997t Iodophors, 899
melatonin for, 1143–1144 hepatitis treated with, 884t, 884–885, Iodoquinol, 929t, 930, 930f
OTC drugs for, 1127t 893t–894t Ion channels, 229. See also specific types
sedative-hypnotics for, 391 Interferon, pegylated in addiction, 576, 577f, 577t
Inspired concentration, 442–444 preparations available, 893t–894t in central nervous system, 369f,
Inspra, 266t with ribavirin, 80t, 85 369–370, 370b, 370t
Institutional review board (IRB), 16 Interferons, 996, 997t ligand-gated, 29f, 29–30, 35
Insulin, 747–749, 769t condylomata acuminata treated with, novel analgesic targets and, 560b
allergy to, 757 892 voltage-gated, 30
case study of, 747, 771 preparations available, 893t–894t, Ionization, of weak acids and bases, 9
chemistry of, 747–748 893–894 Ionization constants, 10t
circulating, 748 Interleukin-1 inhibitors Ionotropic receptors
degludec, 753t–754t, 755 adverse effects of, 658 in addiction, 576, 577f, 577t
degradation of, 748 anakinra, 657 drugs mediating effects via, 583–585.
delivery systems for canakinumab, 657 See also specific drugs
continuous subcutaneous infusion gout treated with, 663 alcohol, 585
devices, 756–757 mechanism of action of, 657 benzodiazepines, 584
portable pen injectors, 756 rheumatoid arthritis treated with, inhalants, 585
detemir, 753t–754t, 755 657–658 ketamine and phencyclidine, 584
diabetic ketoacidosis treated with, 767 rilonacept, 657–658 nicotine, 583–584
durations of action, 754 Interleukin-1α, 657 Ions, 229–230, 230f. See also specific ions
hyperosmolar hyperglycemic syndrome Interleukin-11 (IL-11), 604–605, 606t Ipecac syrup, 1040
treated with, 766 Interleukins, 997t Ipilimumab, 974, 992
immune resistance to, 757, 771 Intermediate-density lipoproteins (IDLs), Ipragliflozin, 261
inhaled, 757 626 Ipratropium (bromide). See also Muscarinic
intermediate-acting, 755–756 Intermittent claudication, 209, 211t receptor blockers (antagonists)
long-acting, 750t, 755–756 International normalized ratio (INR), 615 asthma treated with, 353–354
mixtures of insulins, 756 Interval reduction, in cancer chemotherapy, characteristics of, 135t
preparations available, 753t–754t, 952 chronic obstructive pulmonary disease
753–756 Intestinal flukes, 943 treated with, 130